Extended indication Adezunap monotherapy for add-on treatment of moderate to severe Chronic (back) pain in adults and elderly due to traumatic or post-operative periphera
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Adezunap
Domain Neurological disorders
Reason of inclusion New medicine (specialité)
Main indication Pain
Extended indication Adezunap monotherapy for add-on treatment of moderate to severe Chronic (back) pain in adults and elderly due to traumatic or post-operative peripheral neuropathy, central neuropathy of any genesis or due to diabetic polyneuropathy.
Manufacturer Apurano
Mechanism of action Unknown
Route of administration Sublingual
Therapeutical formulation Spray
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity Unknown
ATMP No
Submission date March 2025
Expected Registration April 2026
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Frequency of administration 1 times a day
Dosage per administration 1,1 mg
References NCT06071936; NCT06071949; NCT06071975; NCT06071962
Additional remarks Sublinguale spray met maximale toepassing van 16 pufjes per dag of een maximale dagelijkse dosis van 17,6mg THC verdeeld over 4 innamen.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information